Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Bibliographic Details
Main Authors: Miles, D., de haas, S., Dirix, L., Romieu, G., Chan, Arlene, Pivot, X., Tomczak, P., Provencher, L., Cortes, J., Delmar, P., Scherer, S.
Format: Journal Article
Published: Nature Publishing Group 2013
Online Access:http://hdl.handle.net/20.500.11937/27277

Internet

http://hdl.handle.net/20.500.11937/27277

Similar Items